Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility

Mary Lynn Davis-Ajami, Jun Wu, Katherine Downton, Emilie Ludeman, Virginia Noxon

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal dialysis, as well as for symptomatic renal anemia in adult patients with renal insufficiency not yet on dialysis. Currently, epoetin zeta can be administered either subcutaneously or intravenously to correct for hemoglobin concentrations ≤10 g/dL (6.2 mmol/L) or with dose adjustment to maintain hemoglobin levels at desired levels not in excess of 12 g/dL (7.5 mmol/L). This review article focuses on epoetin zeta indications in chronic kidney disease, its use in managing anemia of renal origin, and discusses its pharmacology and clinical utility.

Original languageEnglish (US)
Pages (from-to)155-167
Number of pages13
JournalBiologics: Targets and Therapy
Volume8
DOIs
StatePublished - Apr 16 2014
Externally publishedYes

Fingerprint

Clinical Pharmacology
Chronic Renal Insufficiency
Anemia
Kidney
Hemoglobins
Hematinics
Peritoneal Dialysis
Erythropoietin
Marketing
Renal Insufficiency
Renal Dialysis
Dialysis
Pediatrics
epoetin zeta

Keywords

  • Biosimilar
  • Chronic kidney disease
  • Epoetin alfa
  • Erythropoiesis
  • Renal anemia
  • Retacrit®

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Pharmacology (medical)
  • Gastroenterology
  • Rheumatology

Cite this

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. / Davis-Ajami, Mary Lynn; Wu, Jun; Downton, Katherine; Ludeman, Emilie; Noxon, Virginia.

In: Biologics: Targets and Therapy, Vol. 8, 16.04.2014, p. 155-167.

Research output: Contribution to journalReview article

@article{9274388675514ad48963d1f41cdebeb3,
title = "Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility",
abstract = "Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal dialysis, as well as for symptomatic renal anemia in adult patients with renal insufficiency not yet on dialysis. Currently, epoetin zeta can be administered either subcutaneously or intravenously to correct for hemoglobin concentrations ≤10 g/dL (6.2 mmol/L) or with dose adjustment to maintain hemoglobin levels at desired levels not in excess of 12 g/dL (7.5 mmol/L). This review article focuses on epoetin zeta indications in chronic kidney disease, its use in managing anemia of renal origin, and discusses its pharmacology and clinical utility.",
keywords = "Biosimilar, Chronic kidney disease, Epoetin alfa, Erythropoiesis, Renal anemia, Retacrit{\circledR}",
author = "Davis-Ajami, {Mary Lynn} and Jun Wu and Katherine Downton and Emilie Ludeman and Virginia Noxon",
year = "2014",
month = "4",
day = "16",
doi = "10.2147/BTT.S27578",
language = "English (US)",
volume = "8",
pages = "155--167",
journal = "Biologics: Targets and Therapy",
issn = "1177-5475",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility

AU - Davis-Ajami, Mary Lynn

AU - Wu, Jun

AU - Downton, Katherine

AU - Ludeman, Emilie

AU - Noxon, Virginia

PY - 2014/4/16

Y1 - 2014/4/16

N2 - Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal dialysis, as well as for symptomatic renal anemia in adult patients with renal insufficiency not yet on dialysis. Currently, epoetin zeta can be administered either subcutaneously or intravenously to correct for hemoglobin concentrations ≤10 g/dL (6.2 mmol/L) or with dose adjustment to maintain hemoglobin levels at desired levels not in excess of 12 g/dL (7.5 mmol/L). This review article focuses on epoetin zeta indications in chronic kidney disease, its use in managing anemia of renal origin, and discusses its pharmacology and clinical utility.

AB - Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal dialysis, as well as for symptomatic renal anemia in adult patients with renal insufficiency not yet on dialysis. Currently, epoetin zeta can be administered either subcutaneously or intravenously to correct for hemoglobin concentrations ≤10 g/dL (6.2 mmol/L) or with dose adjustment to maintain hemoglobin levels at desired levels not in excess of 12 g/dL (7.5 mmol/L). This review article focuses on epoetin zeta indications in chronic kidney disease, its use in managing anemia of renal origin, and discusses its pharmacology and clinical utility.

KW - Biosimilar

KW - Chronic kidney disease

KW - Epoetin alfa

KW - Erythropoiesis

KW - Renal anemia

KW - Retacrit®

UR - http://www.scopus.com/inward/record.url?scp=84899132159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899132159&partnerID=8YFLogxK

U2 - 10.2147/BTT.S27578

DO - 10.2147/BTT.S27578

M3 - Review article

VL - 8

SP - 155

EP - 167

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

SN - 1177-5475

ER -